Literature DB >> 10506299

The cost of treating substance abuse patients with and without comorbid psychiatric disorders.

R A Hoff1, R A Rosenheck.   

Abstract

OBJECTIVE: Data from a national sample of patients with a primary diagnosis of a substance use disorder were analyzed to examine whether having a comorbid psychiatric diagnosis-a dual diagnosis-was associated with increased costs of health services over a six-year period and whether dually diagnosed patients used particular types of services more frequently.
METHODS: A national sample of substance abuse patients being treated in Veterans Affairs (VA) facilities were classified into two groups-those with a dual diagnosis (N=3, 069) and those with a single diagnosis of a substance use disorder (N=9,538). The sample was identified from two sources during a two-week period in 1990: outpatients in specialty substance abuse clinics and inpatients discharged with a substance-related diagnosis. Administrative data were used to track VA health care utilization and costs between 1991 and 1996.
RESULTS: Dual diagnosis was associated with a significantly increased total cost of care over the six years, which was primarily explained by increased utilization of outpatient psychiatric and substance abuse services. Costs for both groups decreased over time, but they decreased faster among dually diagnosed patients.
CONCLUSIONS: Having a comorbid psychiatric diagnosis appears to consistently increase the cost and utilization of services among patients with a primary diagnosis of a substance use disorder. These results are consistent with previous findings for dually diagnosed patients with a primary psychiatric diagnosis. The increased cost may simply reflect the greater severity of illness among dually diagnosed patients, but it may also indicate fragmented and inefficient service delivery.

Entities:  

Mesh:

Year:  1999        PMID: 10506299     DOI: 10.1176/ps.50.10.1309

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  24 in total

1.  An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program.

Authors:  Kevin W Chen; Annie N Banducci; Leila Guller; Richard J Macatee; Anna Lavelle; Stacey B Daughters; C W Lejuez
Journal:  Drug Alcohol Depend       Date:  2011-04-22       Impact factor: 4.492

2.  Clients with substance abuse and mental health concerns: a guide for conducting intake interviews.

Authors:  Christiane Brems; Mark E Johnson; Lorraine L Namyniuk
Journal:  J Behav Health Serv Res       Date:  2002-08       Impact factor: 1.505

Review 3.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 4.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

5.  Availability of integrated care for co-occurring substance abuse and psychiatric conditions.

Authors:  Lori J Ducharme; Hannah K Knudsen; Paul M Roman
Journal:  Community Ment Health J       Date:  2006-08

6.  Using information technology to evaluate the detection of co-occurring substance use disorders amongst patients in a state mental health system: implications for co-occurring disorder state initiatives.

Authors:  Frederick Y Huang; Douglas M Ziedonis; Hsou Mei Hu; Anna Kline
Journal:  Community Ment Health J       Date:  2007-08-10

7.  Comorbid depression and substance abuse among safety-net clients in Los Angeles: a community participatory study.

Authors:  Evelyn T Chang; Kenneth B Wells; James Gilmore; Lingqi Tang; Anna U Morgan; Starr Sanders; Bowen Chung
Journal:  Psychiatr Serv       Date:  2014-12-01       Impact factor: 3.084

8.  Service utilization during and after outpatient treatment for comorbid substance use disorder and depression.

Authors:  Matthew J Worley; Ryan S Trim; Susan R Tate; Jessica E Hall; Sandra A Brown
Journal:  J Subst Abuse Treat       Date:  2010-07-03

9.  Do client attributes moderate the effectiveness of a group cognitive behavioral therapy for depression in addiction treatment?

Authors:  Sarah B Hunter; Susan M Paddock; Annie Zhou; Katherine E Watkins; Kimberly A Hepner
Journal:  J Behav Health Serv Res       Date:  2013-01       Impact factor: 1.505

10.  Diagnostic cost groups (DCGs) and concurrent utilization among patients with substance abuse disorders.

Authors:  Amy K Rosen; Susan A Loveland; Jennifer J Anderson; Cheryl S Hankin; James N Breckenridge; Dan R Berlowitz
Journal:  Health Serv Res       Date:  2002-08       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.